{"entity":{"id":"alterome-therapeutics","kind":"company","name":"Alterome Therapeutics","aka":[],"tldr":"Alterome Therapeutics makes tablets designed to switch off one specific faulty version of a cancer-driving protein, so that healthy cells are spared. Its two medicines, for cancers driven by mutant AKT1 or mutant KRAS, are in early trials.","summary":"Alterome Therapeutics, Inc. is a clinical-stage precision oncology company at 13480 Evening Creek Drive North, San Diego, California, developing internally discovered small molecules that bind specific mutant forms of cancer drivers. Tanerasertib (ALTA2618) is designed to inhibit the AKT1 E17K mutant and is in the phase 1/1b AKTive-001 study (NCT06533059) in AKT1 E17K-mutant advanced solid tumours, including breast and endometrial cancer; the company announced the first patient dosed on 30 October 2024. ALTA3263, which the company calls a pan-KRAS dual ON/OFF inhibitor, entered a phase 1/1b study (NCT06835569) in KRAS-mutant pancreatic, lung and colorectal cancers, with first dosing announced on 10 March 2025, alone and with cetuximab; first clinical data were due as a late-breaking presentation at the EORTC-NCI-AACR symposium in October 2026. The company launched in January 2022 with a USD 64 million Series A, extended it to nearly USD 100 million in November 2022, and raised a USD 132 million Series B led by Goldman Sachs Alternatives in April 2024. Its first registered cancer trial, NCT06533059, was posted on ClinicalTrials.gov in August 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.alterome.com/"},{"label":"ClinicalTrials.gov: phase 1/1b AKTive-001 trial of tanerasertib (ALTA2618) (NCT06533059)","url":"https://clinicaltrials.gov/study/NCT06533059"},{"label":"ClinicalTrials.gov: phase 1/1b trial of ALTA3263 in KRAS-mutant solid tumours (NCT06835569)","url":"https://clinicaltrials.gov/study/NCT06835569"},{"label":"Company news","url":"https://www.alterome.com/news/"}],"tags":[],"related":[],"cancers":["breast-cancer","endometrial","pancreatic","nsclc","colorectal"],"sections":["targeted-therapy"],"technologies":["pi3k-akt-mtor-inhibitors","kras-inhibitors"],"targets":["akt","kras"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read on 29 October 2026: alterome.com home page and news listing, and the titles of its news posts (which link to the full releases). Founding year not stated on the company website; the company launched publicly in January 2022.","OrbiMed is named as the launch investor only in a trade headline the company reposts; other Series A and B participants were not read.","Trial facts from the ClinicalTrials.gov records NCT06533059 and NCT06835569, read on 29 October 2026; no clinical results were read."],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://www.alterome.com/","stage":"growth","investors":["orbimed"],"funding":[{"round":"Series A","year":2022,"amountUsd":64000000,"source":"https://www.alterome.com/alterome-therapeutics-launches-with-64m-series-a-financing/","note":"Launch round; the company reported in November 2022 that it had extended the Series A to nearly USD 100 million."},{"round":"Series B","year":2024,"amountUsd":132000000,"source":"https://www.alterome.com/alterome-therapeutics-raises-132-million-in-series-b-financing-led-by-goldman-sachs-alternatives/","note":"Led by Goldman Sachs Alternatives."}]},"route":"/companies/alterome-therapeutics/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"},{"id":"pi3k-akt-mtor-inhibitors","kind":"technology","name":"PI3K, AKT and mTOR inhibitors","route":"/technologies/pi3k-akt-mtor-inhibitors/"}],"target":[{"id":"akt","kind":"target","name":"AKT","route":"/targets/akt/"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"company":[{"id":"orbimed","kind":"company","name":"OrbiMed","route":"/companies/orbimed/"}]}}